Author

D. Dabbagh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

B. Hetrick· 3 shared S. He· 3 shared Y. Wu· 3 shared A. Andalibi· 2 shared A. A. Waheed· 1 shared A. Luchini· 1 shared A. Narayanan· 1 shared A. Pak· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

B. Hetrick

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of the SHREK family of proteins as broad-spectrum host antiviral factors

D. Dabbagh, S. He, B. Hetrick, L. Chilin, A. Andalibi, Y. Wu

This study identifies the SHREK family of proteins as broad-spectrum antiviral factors that inhibit HIV-1 and other viruses by blocking virus particle attachment to target cells.

bioRxiv · Feb 2, 2021Microbiology

Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, viral variants, and antiviral drugs

B. Hetrick, S. He, L. D. Chilin, D. Dabbagh, F. Alem, A. Narayanan, A. Luchini, T. Li, X. Liu, J. Copeland, A. Pak, T. Cunningham, L. Liotta, E. Petricoin, A. Andalibi, Y. Wu

This paper develops a hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening of neutralizing antibodies, viral variants, and antiviral drugs, showing increased infectivity of variants and enhanced neutralization by post-vaccination serum.

bioRxiv · Dec 22, 2020 · PreprintMicrobiology

PSGL-1 inhibits the virion incorporation of SARS-CoV and SARS-CoV-2 spike glycoproteins and impairs virus attachment and infectivity

S. He, A. A. Waheed, B. Hetrick, D. Dabbagh, I. V. Akhrymuk, K. Kehn-Hall, E. O. Freed, Y. Wu

The paper shows PSGL-1 inhibits SARS-CoV and SARS-CoV-2 spike glycoprotein incorporation into pseudovirions, blocking virus attachment and infectivity.

bioRxiv · May 1, 2020 · PreprintMicrobiology